Sat, Dec 27, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Alternative Market Briefing

Investors are forcing hedge fund managers to abandon '2 and 20’ fee model

Monday, September 09, 2013

Precy Dumlao, Opalesque Asia:

Dissatisfied investors are forcing many hedge fund managers to rethink and even completely abandon the traditional '2 and 20’ fee model, according to The Wall Street Journal.

Most hedge fund managers are now charging approximately 1.6% for annual management fee and 18% on profits, "according to industry surveys and interviews with industry executives." The difference in the percentage could translate to hundreds of millions of dollars as last year, the hedge fund industry took in about $50.5bn in management and performance fees, Hedge Fund Research (HFR) is reported as saying.

The pressure are coming mostly from pension funds and other institutional investors, which have billions of dollars into hedge fund portfolios.

Those who were forced to reduce their management and performance fees are hedge funds focused on stocks and commodities as these strategies have not been generating high returns lately, the report added.

One of these industry surveys came from Preqin, a research house, which recently showed that hedge funds that charge the highest fees achieved the best returns in four of the past six years (See Opalesque article here).

Amy Bensted, Head of Hedge Funds Products at Preqin said:......................

To view our full article Click here

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Hong Kong-Shanghai stock link fails to live up to expectation so far[more]

    Komfie Manalo, Opalesque Asia: In a report, Reuters said that demand has been subdued with the bulk of activities coming from short-term speculative investors. Las

  2. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  3. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  4. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for

  5. CFTC Revokes Registrations of Illinois Resident Aleks A. Kins and Chicago-based AlphaMetrix, LLC[more]

    Matthias Knab, Opalesque: The U.S. Commodity Futures Trading Commission (CFTC) today announced that it has revoked the registration of Aleks A. Kins of Chicago, Illinois, as an Associated Person and the registrations of AlphaMetrix, LLC (AlphaMetrix), a Delaware limited liability company with its